BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

Novo Nordisk’s deal to acquire Corvidia for $725 million up front gives the Danish pharma a Phase IIb atherosclerosis asset that expands its range in cardiometabolic diseases adjacent to its core business of treating diabetes...
BioCentury | May 29, 2020
Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

Incoming CEO David Loew will arrive as Ipsen tries to recover from setbacks that have hobbled development of palovarotene, one of its two candidates to treat rare disease FOP and the key to its billion-dollar...
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

Exelixis jumped $4.14 (21%) to $23.58 on Monday, pushing its valuation above $7 billion, after the biotech and partners Bristol Myers Squibb and Ipsen said the combination of Opdivo nivolumab plus Cabometyx cabozantinib generated positive...
BioCentury | Apr 6, 2020
Product Development

Immunomedics doubles in value on Phase III update for TNBC therapy ahead of June PDUFA; names Semerjian CEO

After halting a Phase III trial early due to efficacy in the difficult setting of triple-negative breast cancer, Immunomedics named a new, commercially-experienced CEO to help the biotech transition into a commercial launch phase. Immunomedics...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B. Takeda Ventures Inc. led the financing with...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
Items per page:
1 - 10 of 924
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

Novo Nordisk’s deal to acquire Corvidia for $725 million up front gives the Danish pharma a Phase IIb atherosclerosis asset that expands its range in cardiometabolic diseases adjacent to its core business of treating diabetes...
BioCentury | May 29, 2020
Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

Incoming CEO David Loew will arrive as Ipsen tries to recover from setbacks that have hobbled development of palovarotene, one of its two candidates to treat rare disease FOP and the key to its billion-dollar...
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

Exelixis jumped $4.14 (21%) to $23.58 on Monday, pushing its valuation above $7 billion, after the biotech and partners Bristol Myers Squibb and Ipsen said the combination of Opdivo nivolumab plus Cabometyx cabozantinib generated positive...
BioCentury | Apr 6, 2020
Product Development

Immunomedics doubles in value on Phase III update for TNBC therapy ahead of June PDUFA; names Semerjian CEO

After halting a Phase III trial early due to efficacy in the difficult setting of triple-negative breast cancer, Immunomedics named a new, commercially-experienced CEO to help the biotech transition into a commercial launch phase. Immunomedics...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B. Takeda Ventures Inc. led the financing with...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
Items per page:
1 - 10 of 924